Fiscal 2026 funding discussions to dominate House, Senate agenda
"Any effort to rescind appropriated funds without congressional approval is a clear violation of the law," Senate Appropriations Chair Susan Collins, R-Maine, said in a statement.
Search Roll Call
Search the Roll Call archive by keyword, date, Congress, section, or tags.
136 results for "M/R"
Utah judge tosses congressional maps, creating Democratic opportunity
"The Legislature is directed to design and enact a remedial congressional redistricting map in conformity with Proposition 4’s mandatory redistricting standards and requirements," Judge Dianna M.
First three fiscal 2026 appropriations bills pass Senate
"Needing help with your finances doesn’t make you mentally incapacitated or mentally incompetent," Boozman, R-Ark., said. Murphy’s amendment was rejected, 44-51.
Republicans, appropriators dominate House earmarks
James R. Comer, the Oversight and Government Reform panel chairman.Â
Trust on the tarmac: Lawmakers who travel together legislate together
Kirsten Gillibrand, D-N.Y., and Joni Ernst, R-Iowa, had very little in common. Gillibrand was born in upstate New York and worked for a Manhattan-based law firm.
Democrats have long outpaced Republicans in deaths in officeÂ
That was quickly followed by the deaths of two veteran Democrats: Raúl M. Grijalva, 77, of Arizona, who for years held the top slot on the Natural Resources Committee, and then Virginia’s Gerald E.
Republicans ready assault on California animal welfare law
Ashley Hinson, R-Iowa, and other farm-state colleagues prepared to introduce industry-backed legislation that they’ve dubbed the "Save Our Bacon Act."
House sends $9 billion rescissions package to president’s desk
Richard M. Burr. The North Carolina Republican was displeased at the time with proposed cuts to the Land and Water Conservation Fund.
Senate GOP pushes spending bills as Democratic anger builds
Lisa Murkowski, R-Alaska, both echoed that criticism in softer tones.
Senators face crucial vote on $9.4 billion rescissions package
When asked if Republicans had enough votes to get on the bill, Senate Majority Leader John Thune, R-S.D., said negotiations were still ongoing on potential amendments.
Mammoth budget bill heads to Trump’s desk in time for July Fourth
Brian Fitzpatrick, R-Pa., and Thomas Massie, R-Ky., were the only GOP "no" votes.
GOP leaders work to convince House holdouts on budget package
Eric Burlison, R-Mo., who’s been railing against the bill on social media.
Vibe shift in House as Trump, GOP leaders begin to flip votes
Josh Brecheen, R-Okla., declined to comment after meeting with Vought.
‘Big, beautiful’ budget reconciliation package passes Senate
Thune, Majority Whip John Barrasso, R-Wyo., Senate Finance Chairman Michael D. Crapo, R-Idaho, and Sen. Dan Sullivan, R-Alaska, all were seen huddling with Murkowski on and off for several hours.
Roll Call goes platinum
Speaker Mike Johnson, R-La., Vice President JD Vance, Senate Majority Leader John Thune, R-S.D., and House Minority Leader Hakeem Jeffries, D-N.Y., were all years from being born.Â
Delicate balancing act for Senate on reconciliation tax package
Thom Tillis, R-N.C., making those tax breaks more generous than they are currently to become part of the package, the lobbyist said.
A look at key flashpoints in the coming Senate reconciliation debate
And Senate Agriculture Republicans come largely from small rural states. — Olivia M.
No cameras, please: Some offices in Congress warn visitors not to film
Walking up and down the halls of buildings on the House side earlier this month, we counted 12 Republicans and four Democrats: Aaron Bean, R-Fla.; Darrell Issa, R-Calif.; David Valadao, R-Calif.; Erin
GOP budget vote goes down to the wire amid conservative pushback
Chip Roy, R-Texas, and Ralph Norman, R-S.C. — have been part of the negotiations from the start, nearly derailing the measure in the Budget Committee last week. Roy, Norman, Harris and Rep.Â
Rare Disease Patients Await Congressional Action on Life-Saving Treatments
For the vast majority (over 90%) of rare diseases lacking FDA-approved treatments, reducing barriers to R&D investment must remain the priority—especially when reducing these barriers would require remarkably